

Neuro-Innovators Appoints Ray Jordan to Board of Directors

Veteran corporate affairs and communications executive joins Neuro-Innovators's board as the company advances its neurorestorative pipeline

BOSTON, MA, UNITED STATES, September 21, 2026

/EINPresswire.com/ -- [Neuro-Innovators, Inc.](#), a biotechnology company advancing therapies designed to promote neurological recovery following injury and disease, today announced the appointment of Ray Jordan as lead preferred shareholder director, on its board of directors.



"Ray is a seasoned investor who brings a rare combination of global healthcare leadership, strategic communications expertise and experience helping innovative companies navigate periods of growth and increased visibility," said Howison Schroeder, CEO of Neuro-Innovators. "As we advance NIV-001 in the clinic and prepare Neuro-Innovators for its next stage, his counsel will be invaluable in strengthening our corporate strategy, engaging key stakeholders and positioning the company for long-term success."

Ray Jordan, managing director of Elmstead Partners LLC and Putnam Insights LLC, is a corporate affairs leader with a track record of driving reputational growth across healthcare, technology, biotechnology and consumer industries. Previously, he held senior corporate affairs and communications leadership roles at Moderna, Amgen and Johnson & Johnson, and served as senior communications and strategic counsel at Pfizer. Throughout his career, Jordan has been recognized by industry sources including PRWeek and PProvoke Media, and each of his corporate employers has earned distinctions such as FORTUNE's World's Most Admired Companies and the Dow Jones Sustainability Index.

"Neuro-Innovators is pursuing an ambitious and deeply important goal: helping people recover function following stroke and other neurological injuries," said Jordan. "The team has translated a compelling scientific rationale into a capital-efficient clinical program with the potential to address a significant unmet need. I am honored to join the board and support Howison and the team as they advance NIV-001, build awareness of Neuroplastic Medicine™ and develop the

partnerships needed to reach more patients.”

The appointment comes as Neuro-Innovators advances NIV-001, its lead investigational program for chronic stroke recovery. The company recently began dosing patients in a clinical study at Spaulding Rehabilitation Hospital, part of Mass General Brigham.

About Neuro-Innovators

Neuro-Innovators is a first in class clinical-stage pharmaceutical company focused on developing compound therapies designed to support biological pathways associated with neurological recovery following stroke, brain injury, and other neurological conditions. The company’s mission is to improve functional outcomes for patients while reducing the long-term personal and societal burden of neurologic disability.

Healing Brains with Neuroplastic Medicine™

For more information, please visit www.neuro-innovators.com or follow us on LinkedIn (<https://www.linkedin.com/company/neuro-innovators>).

Media Contact

Madelyn De Los Santos
Putnam Insights LLC
madelyn@putnaminsights.com

This press release can be viewed online at: <https://www.einpresswire.com/article/943384082>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.